RESUMO
BACKGROUND: Transition from pediatric to adult care of patients affected by Inflammatory Bowel Disease (IBD) is a critical step that needs specific care and multidisciplinary involvement. The aim of our study was to evaluate the outcome of the transition process of a cohort of IBD patients, exploring their readiness and the possible impact on quality of life. METHODS: This observational study followed transitioned IBD patients from pediatric to adult care. Transition was carried-out through combined visits, jointly performed by the pediatrician and the adult gastroenterologist. Clinical data were collected before and after transition. A subgroup of patients was submitted to an anonymous online questionnaire of 38 items based on the validated questionnaires TRAQ and SIBDQ within the first 6 months from the beginning of the transition process. RESULTS: Eighty-two patients with IBD were enrolled, with a mean age at transition of 20.2±2.7 years. Before transition, 40.2% of patients already had major surgery and 64.6% started biologics. At transition, 24% of patients were in moderate to severe active phase of their disease and 40% of them had already been treated with ≥ 2 biologics. The mean score of the TRAQ questionnaires collected is 3.4±1.5 and the mean score of SIBDQ is 53.9±9.8. A significant association was found between a TRAQ mean score > 3 and a SIBDQ > 50 (p=0.0129). Overall, 75% of patients had a positive opinion of the transition model adopted. CONCLUSIONS: A strong association has been found between TRAQ and SIBDQ questionnaires, showing how transition readiness has a direct impact on the quality of life of the young adult with IBD.
Assuntos
Doenças Inflamatórias Intestinais/terapia , Transição para Assistência do Adulto , Adolescente , Criança , Feminino , Humanos , Itália , Masculino , Inquéritos e Questionários , Adulto JovemAssuntos
Anti-Inflamatórios/uso terapêutico , Colangite Esclerosante/tratamento farmacológico , Colite Ulcerativa/tratamento farmacológico , Fármacos Gastrointestinais/uso terapêutico , Infliximab/uso terapêutico , Adolescente , Anti-Inflamatórios/efeitos adversos , Colangite Esclerosante/diagnóstico , Colangite Esclerosante/imunologia , Colite Ulcerativa/diagnóstico , Colite Ulcerativa/imunologia , Feminino , Fármacos Gastrointestinais/efeitos adversos , Humanos , Infliximab/efeitos adversos , Masculino , Estudos Retrospectivos , Resultado do TratamentoRESUMO
Inflammatory bowel diseases (IBDs) represent a group of intestinal disorders with a chronic and relapsing inflammation of the gut, and with a potential risk of systemic involvement of other organs and systems. Over the pediatric age, an incidence higher than 20% of developing extraintestinal manifestation during follow-up has been reported. The liver and the biliary system are frequently involved, and primary sclerosing cholangitis (PSC) is the most predominant entity with an incidence rate of 6.4-7.8% in children. PSC recognizes a multifactorial pathogenesis, and so far a not fully known mechanism for this association. The peculiar phenotype and the distinct clinical course of patients with IBD and PSC-associated make this 'linkage' an attractive study model to better understand mechanisms underlying these diseases. Approaching to these patients is complex and multidisciplinary, and a unique therapeutic strategy has not been standardized yet. New medications are being studied; however, further studies are needed to fully understand the pathogenesis and to improve the care of these patients. The aim of this paper is to review the recent literature regarding hepatobiliary involvement in IBD patients, with particular attention to PSC, and to provide the latest information for a correct diagnosis and appropriate management.
Assuntos
Doenças Autoimunes/complicações , Colangite Esclerosante/complicações , Doenças Inflamatórias Intestinais/complicações , Fígado/patologia , Doenças Autoimunes/terapia , Criança , Colangite Esclerosante/terapia , Humanos , Doenças Inflamatórias Intestinais/terapia , Transplante de Fígado , PediatriaRESUMO
INTRODUCTION: The incidence of inflammatory bowel disease (IBD) has increased over the last 50 years. It is now recognized that several genetic defects can express an IBD-like phenotype at very early onset (<6 years). AREAS COVERED: The aim of this review was to update knowledge concerning the specificity of IBD at onset <6 years, which can include conventional/standard IBD as well as monogenic IBD-like diseases. Expert commentary: We found that females are less prone than males to develop monogenic disorders, which have X-linked heritability in several cases. Furthermore, the Crohn's Diseases (CD) subtype seems to be suggestive of monogenic disorders while Unclassified IBD (IBDU) subtype is predominantly found in conventional/standard IBD at onset <6 years. Isolated colonic location is prevalent in both the subsets of IBD at onset <6 years if compared to IBD at later onset. Monogenic disorders require more aggressive medical and surgical treatments and can be complicated by the occurrence of lymphomas.
Assuntos
Colo/imunologia , Doenças Inflamatórias Intestinais/epidemiologia , Idade de Início , Animais , Pré-Escolar , Predisposição Genética para Doença , Humanos , Incidência , Doenças Inflamatórias Intestinais/genética , Fenótipo , PrevalênciaRESUMO
Thalidomide has anti-inflammatory and anti-angiogenetic activity that makes it suitable for treating inflammatory bowel diseases (IBD). The recent guidelines from the European Crohn's and Colitis Organization/European Society for Pediatric Gastroenterology Hepatology and Nutrition conclude that thalidomide cannot be recommended in refractory pediatric Crohn's disease but that it may be considered in selected cohorts of patients who are not anti-TNFα agent responders. The main adverse effect is the potential teratogenicity that renders the long-term use of thalidomide problematic in young adults due to the strict need for contraceptive use. In short-term use it is relatively safe; the most likely adverse effect is the neuropathy, which is highly reversible in children. So far the use of thalidomide is reported in 223 adult and pediatric IBD patients (206 with Crohn's disease). In the following sections, the authors will discuss efficacy and safety of thalidomide, in the short-term treatment of IBD.
Assuntos
Imunossupressores/uso terapêutico , Doenças Inflamatórias Intestinais/tratamento farmacológico , Talidomida/uso terapêutico , Criança , Europa (Continente) , Humanos , Imunossupressores/efeitos adversos , Teratoma/etiologia , Talidomida/efeitos adversos , Fatores de Tempo , Fator de Necrose Tumoral alfa/antagonistas & inibidores , Adulto JovemRESUMO
It is reported that a pancreatic disease may precede the diagnosis of inflammatory bowel disease (IBD) both in children and in adults. Idiopathic chronic pancreatitis, however, occasionally co-exists with the IBD, mainly at pediatric age. We report a case of a patient who progressively developed the features of a chronic pancreatitis, before the diagnosis of Crohn's Disease (CD). Ten months after the onset of the first episode of pancreatitis the patient developed bloody diarrhea, mucus stools and biochemical findings of inflammation. The colonoscopy revealed a diffuse colitis without involvement of the last loop and the gastroscopy showed inflammation of the iuxta-papillary area. The histological findings confirmed the diagnosis of CD that involved the colon and the duodenum. In conclusion, in children the idiopathic chronic pancreatitis may be an unusual presentation of CD. Thus, if other known cause of chronic pancreatitis are not found, a not invasive work up to exclude the IBD should be warranted. An early coincidental diagnosis of the IBD may delay the progression of the pancreatic disease.
Assuntos
Doença de Crohn/complicações , Pancreatite Crônica/etiologia , Adolescente , Criança , Pré-Escolar , Colonoscopia , Doença de Crohn/diagnóstico , Doença de Crohn/terapia , Feminino , Fármacos Gastrointestinais/uso terapêutico , Gastroscopia , Humanos , Imunossupressores/uso terapêutico , Pancreatite Crônica/diagnóstico , Pancreatite Crônica/terapia , Valor Preditivo dos Testes , Recidiva , Esfinterotomia Endoscópica/instrumentação , Stents , Resultado do TratamentoRESUMO
PURPOSE: Several researchers have found that plasma citrulline could be a marker of reduced enterocyte mass. The aim of this study was to assess the relationship between plasma citrulline and bowel inflammation and/or disease location in pediatric and adolescent Crohn's disease (CD) patients. METHODS: Between January 2008 and January 2010, 31 CD patients and 44 controls were included in our study, and 15 out of the 31 CD patients continued a prospective survey. We evaluated the differences between groups, at baseline, in plasma citrulline and glutamine and between their baseline and final values during the prospective survey, and correlation between baseline values of citrulline and duration of disease, C-reactive protein, and fecal calprotectin. RESULTS: Mean citrulline value was 33.0 ± 7.5 µmol/L in controls and 23.5 ± 8.4 µmol/L in CD patients (P < 0.0001). Plasma citrulline was significantly lower in patients with small bowel (SB) location than in patient with only ileo-colon disease (14.2 ± 5.5 and 24.7 ± 8.0, respectively; P = 0.0037). Citrulline ≤22 µmol/L reached sensitivity of 100% (95% confidence interval (CI) 54-100) and specificity of 98% (CI 89-99) in differentiating control subjects from CD with SB location. CONCLUSIONS: CD patients have reduced concentration of plasma citrulline than controls. Intestinal damage rather than inflammation seems to be responsible for the reduced biosynthesis of citrulline, which decreases particularly in CD patients with SB location. This finding suggests the potential role of citrulline as marker of disease location, but future works will be needed to confirm this suggestion.
Assuntos
Citrulina/sangue , Doença de Crohn/sangue , Inflamação/sangue , Intestinos/patologia , Relatório de Pesquisa , Adolescente , Biomarcadores/sangue , Proteína C-Reativa/metabolismo , Criança , Fezes , Glutamina/sangue , Humanos , Complexo Antígeno L1 Leucocitário , Curva ROCRESUMO
BACKGROUND: Inflammatory bowel disease (IBD) has been associated with several polymorphisms in genes likely involved in innate immune responses and integrity of epithelial mucosal barrier. A major role in adult Crohn's disease (CD) has been defined for 3 polymorphisms in the CARD15 gene, whereas variants in the SLC22A4, SLC22A5, and DLG5 genes could have a minor contribution to IBD susceptibility. METHODS: We analyzed a panel of 6 polymorphisms within these genes in 227 Italian early-onset IBD patients (134 CD, 93 ulcerative colitis [UC]; age at diagnosis Assuntos
Doenças Inflamatórias Intestinais/genética
, Peptídeos e Proteínas de Sinalização Intracelular/genética
, Proteínas de Membrana/genética
, Proteínas de Transporte de Cátions Orgânicos/genética
, Polimorfismo Genético
, Proteínas Supressoras de Tumor/genética
, Adolescente
, Idade de Início
, Criança
, Colite Ulcerativa/genética
, Doença de Crohn/genética
, Genótipo
, Humanos
, Itália
, Proteína Adaptadora de Sinalização NOD2
, Simportadores